NCT04697446 2021-08-10
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Blueprint Medicines Corporation
Unknown
Blueprint Medicines Corporation
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ludwig-Maximilians - University of Munich